FDA approvals usher in the post-interferon era in HCV.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed, 29 citations in OpenAlex.

1. Nucleotide Metabolism in Health and Disease.MedComm · 2026
   Review
2. Serum cytokines in periodontal diseases.Periodontology 2000 · 2025
   Review
3. Efficient Synthesis and Docking Studies of Novel Benzothiazole-Based Pyrimidinesulfonamide Scaffolds as New Antiviral Agents and Hsp90α Inhibitors.ACS omega · 2020
   Article
4. Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism.Cancers · 2018
   Review
5. Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C.Israel journal of health policy research · 2017
   Article
6. A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection.Iranian Red Crescent medical journal · 2016
   Article
7. Trends in clinical development timeframes for antiviral drugs launched in the UK, 1981-2014: a retrospective observational study.BMJ open · 2015
   Observational
8. Industry chases pan-genotypic and shorter HCV treatments.Nature biotechnology · 2015
   Article
9. Measuring fate and rate of single-molecule competition of amplification and restriction digestion, and its use for rapid genotyping tested with hepatitis C viral RNA.Angewandte Chemie (International ed. in English) · 2014
   Article
10. Sovaldi makes blockbuster history, ignites drug pricing unrest.Nature biotechnology · 2014
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as